This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. PACS, ARDT, SEM, QDEL, AGIO, CERT, PGNY, LMAT, BCRX, and GRALShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include PACS Group (PACS), Ardent Health (ARDT), Select Medical (SEM), QuidelOrtho (QDEL), Agios Pharmaceuticals (AGIO), Certara (CERT), Progyny (PGNY), LeMaitre Vascular (LMAT), BioCryst Pharmaceuticals (BCRX), and GRAIL (GRAL). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Its Competitors PACS Group Ardent Health Select Medical QuidelOrtho Agios Pharmaceuticals Certara Progyny LeMaitre Vascular BioCryst Pharmaceuticals GRAIL Lionheart Acquisition Co. II (NASDAQ:LCAP) and PACS Group (NYSE:PACS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Do analysts recommend LCAP or PACS? PACS Group has a consensus target price of $34.29, indicating a potential upside of 166.81%. Given PACS Group's stronger consensus rating and higher probable upside, analysts clearly believe PACS Group is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PACS Group 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is LCAP or PACS more profitable? PACS Group's return on equity of 0.00% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Lionheart Acquisition Co. IIN/A -44.30% 1.39% PACS Group N/A N/A N/A Which has preferable earnings & valuation, LCAP or PACS? PACS Group has higher revenue and earnings than Lionheart Acquisition Co. II. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLionheart Acquisition Co. IIN/AN/A$3.21MN/AN/APACS Group$3.56B0.55$112.87MN/AN/A Which has more volatility and risk, LCAP or PACS? Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, PACS Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Does the media favor LCAP or PACS? In the previous week, PACS Group had 1 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 1 mentions for PACS Group and 0 mentions for Lionheart Acquisition Co. II. Lionheart Acquisition Co. II's average media sentiment score of 0.00 beat PACS Group's score of -0.11 indicating that Lionheart Acquisition Co. II is being referred to more favorably in the media. Company Overall Sentiment Lionheart Acquisition Co. II Neutral PACS Group Neutral SummaryPACS Group beats Lionheart Acquisition Co. II on 8 of the 10 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$497.90M$151.90M$5.58B$9.01BDividend YieldN/AN/A5.25%4.03%P/E RatioN/A0.5727.5120.20Price / SalesN/A22.10415.84172.51Price / Cash20.6411.7037.0657.97Price / Book-9.473.358.085.61Net Income$3.21M$1.30M$3.17B$248.50M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$26.98+0.7%N/A+6,417.4%$497.90MN/A0.003PACSPACS Group2.8984 of 5 stars$12.93+0.1%$34.29+165.2%-57.3%$1.97B$3.11B0.0032,433ARDTArdent Health3.5433 of 5 stars$13.74+0.6%$20.67+50.4%N/A$1.95B$5.97B8.4324,900SEMSelect Medical5 of 5 stars$15.23+0.3%$26.00+70.8%-59.2%$1.95B$5.19B11.3644,100Positive NewsQDELQuidelOrtho4.4416 of 5 stars$29.79+3.4%$44.33+48.8%+5.2%$1.95B$2.78B-5.996,600AGIOAgios Pharmaceuticals4.0801 of 5 stars$34.37+3.3%$58.60+70.5%-8.5%$1.93B$36.50M3.06390CERTCertara4.7153 of 5 stars$11.52-1.5%$15.67+36.0%-18.2%$1.90B$385.15M-576.001,546News CoverageAnalyst RevisionGap DownPGNYProgyny1.4621 of 5 stars$22.06+0.3%$23.45+6.3%-15.6%$1.89B$1.17B38.70310Trending NewsAnalyst UpgradeAnalyst RevisionLMATLeMaitre Vascular1.9085 of 5 stars$83.69+0.8%$97.83+16.9%+1.1%$1.88B$219.86M42.27490BCRXBioCryst Pharmaceuticals4.4684 of 5 stars$9.00+0.4%$16.70+85.6%+39.8%$1.87B$450.71M-34.62530GRALGRAIL0.7798 of 5 stars$49.23-4.3%$31.50-36.0%N/A$1.85B$125.60M0.001,360 Related Companies and Tools Related Companies PACS Alternatives ARDT Alternatives SEM Alternatives QDEL Alternatives AGIO Alternatives CERT Alternatives PGNY Alternatives LMAT Alternatives BCRX Alternatives GRAL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LCAP Stock Alerts